Roundtable, which included a special fireside chat with Masimo Founder & Chairman Joe Kiani and President Bill Clinton, held at Clinton Foundation offices in New York City

Participants included national leaders in healthcare, education, and policy

Masimo (NASDAQ: MASI) and the Clinton Foundation today hosted an in-person roundtable addressing the overdose and addiction crisis. Joe Kiani, Founder and CEO of Masimo, and President Bill Clinton, 42^nd President of the United States and Founder and Board Chair, Clinton Foundation, led the conversation at the Foundation offices in New York City. Participants included national opioid and addiction specialists, hospital and academic executives, community members, and local, state, and national elected officials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230621380251/en/

Overdose and Addiction Crisis Roundtable Hosted by Masimo and Clinton Foundation (Photo: Business Wire)

The event brought together experts and peers to collaborate on evidence-based solutions designed to help patients affected by the overdose and addiction crisis. The discussion highlighted solutions such as Bridge™ and Opioid Halo™ from Masimo—the first winner of the FDA’s Opioid Innovation Challenge to have an authorized device addressing the crisis—designed to prevent overdose, save lives, and reduce the stigma surrounding opioid use. Attendees also had the opportunity to test both products onsite at an Opioid Safety Demo table.

Joe Kiani, Founder, Chairman and CEO of Masimo, said, “At Masimo, we are committed to creating evidence-based solutions that fill in existing gaps in patients’ support network. We must collectively work together to eliminate the stigma around addiction and fight the opioid crisis, one of our nation’s most pressing public health challenges and the leading cause of accidental deaths in the U.S. My hope is that our conversation today will inspire a greater dialogue around how communities can better support opioid users in the hospital and at home, reducing deaths and stopping the cycle of addiction.”

President Bill Clinton said, “Overdose deaths reached an all-time high last year with more than 109,000 lives lost. If we’re going to have a chance at reversing the tide, it’s going to take all of us — more hospitals and clinics, more stakeholders and community leaders, and more innovators like Joe Kiani and Masimo. Their commitment to fighting the overdose crisis has led to breakthroughs that can prevent overdose deaths and help people on the road to recovery.”

Among the key participants in the roundtable today were:

Chris Thrasher, Chief Executive Officer of Substance Use Disorders and Recovery, Clinton Foundation, who said: “A key component missing from the conversation is how can technology help solve this crisis. With these evidence-based technological solutions, we can and will save one life at a time.”

Seonaid Nolan, M.D, Assistant Professor, Department of Medicine, University of British Columbia, said: “Collective efforts are better than each individual effort. To turn the tide, it is important we come together, across disciplines, to develop a comprehensive approach to linking people to the services they need at the time they want it.”

Chief Tom Synan, Chief of Police, Newtown Police Department, Ohio, said: “We must come together to find new ways to help serve those with substance use disorder. We need to fill in the gaps to provide better service to those in need and utilize evidence-based technologies like Bridge which can be used in various sectors of the community, such as the justice system and health care system.”

Aldo Carmona, M.D., Senior VP of Clinical Integration and Chairman of Anesthesia, St. Luke's University Health Network, said: “We know the opioid crisis significantly affects families. Understanding people’s genetic makeup matters and it could help us identify high-risk populations.”

Sean O’Donnell, MS, Executive Director, Foundation for Recovery, said: “We need more innovation in this space. We’ve got heart. We’ve got data. We’ve been studying this crisis and the solutions. Now, we need to ensure those who need these products most can access them. It is time for action.”

Ryan Hampton, Co-Founder and Executive Director, Mobilize Recovery, said: “People are inspired and ready to take action. There is a lot of innovation and intent to break silos between sectors. When we come together and share our learnings, we make giant strides towards addressing this crisis by making actionable commitments for impactful change.”

Karl Leonard, Sheriff, Chesterfield County Sheriff’s Office, Virginia, said: “Today’s event brought together leaders across disciplines to discuss how we can effectively and efficiently work together to build momentum.”

Jeffrey A. Thomas, MHS, LPC, CACDC, Chief Executive Officer, White Deer Run, said: “We need to further implement technology in the treatment of opioid dependence and move away from outdated techniques and practices. Opioid users who are chemically dependent desire a powerful, timely solution, and Bridge delivers just that; we were astounded by how well the device worked and now use it to reduce recidivism and reduce abandonment of treatment. We’re a great case study for abatement funds to support the community in need.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.¹ Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,² improve CCHD screening in newborns³ and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.^4-7 Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,⁸ and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.⁹ In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^®, Radius PPG^®, and Radius VSM™, portable devices like Rad-67^®, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris^® Gateway, iSirona™, Patient SafetyNet, Replica^®, Halo ION^®, UniView^®, UniView :60™, and Masimo SafetyNet^®. Its growing portfolio of health and wellness solutions includes Radius Tº^®, Masimo W1™, and Masimo Stork™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
8. Estimate: Masimo data on file.
9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique technologies contribute to positive user experience and user safety; risks related to our belief that Masimo technology breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230621380251/en/